These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1156 related items for PubMed ID: 21354370

  • 41. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
    Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ.
    J Clin Oncol; 2007 Sep 01; 25(25):3859-65. PubMed ID: 17646669
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.
    J Clin Oncol; 2011 Sep 01; 29(25):3351-7. PubMed ID: 21788566
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE.
    Lancet Oncol; 2012 Mar 01; 13(3):300-8. PubMed ID: 22277837
    [Abstract] [Full Text] [Related]

  • 48. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B.
    Cancer; 2012 Apr 15; 118(8):1982-8. PubMed ID: 21887681
    [Abstract] [Full Text] [Related]

  • 49. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
    Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F.
    J Clin Oncol; 2009 Dec 20; 27(36):6129-34. PubMed ID: 19917839
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators.
    N Engl J Med; 2006 Feb 23; 354(8):809-20. PubMed ID: 16495393
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant (HERA) Trial Study Team.
    N Engl J Med; 2005 Oct 20; 353(16):1659-72. PubMed ID: 16236737
    [Abstract] [Full Text] [Related]

  • 55. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B.
    JAMA Oncol; 2016 Aug 01; 2(8):1040-7. PubMed ID: 27100299
    [Abstract] [Full Text] [Related]

  • 56. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.
    Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.
    Breast Cancer Res Treat; 2008 Jun 01; 109(3):559-66. PubMed ID: 17661170
    [Abstract] [Full Text] [Related]

  • 57. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
    Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H, TH3RESA study collaborators.
    Lancet Oncol; 2014 Jun 01; 15(7):689-99. PubMed ID: 24793816
    [Abstract] [Full Text] [Related]

  • 58. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM.
    J Clin Oncol; 2007 Feb 20; 25(6):634-41. PubMed ID: 17308268
    [Abstract] [Full Text] [Related]

  • 59. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
    Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I, Lindquist DL, Holmes FA, Allison MAK, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, Wang Y, Asmar L, Robert NJ, O'Shaughnessy J.
    Lancet Oncol; 2013 Oct 20; 14(11):1121-1128. PubMed ID: 24007746
    [Abstract] [Full Text] [Related]

  • 60. Is there a qualitative interaction between adjuvant trastuzumab and size of the primary tumor in breast cancer?
    Vesely P, Melichar B.
    Neoplasma; 2008 Oct 20; 55(5):375-80. PubMed ID: 18665746
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.